A nationwide shortage of estradiol patches — a common form of hormone therapy — is making it harder for patients to fill prescriptions, with availability varying by pharmacy and region.
The squeeze is driven by a surge in demand. More perimenopausal and postmenopausal people are using hormone replacement therapy (HRT) for symptoms like hot flashes, night sweats and bone loss, and transgender and non-binary people use estradiol for gender-affirming care. Demand rose further after the FDA removed a long-standing boxed warning on some HRT products in November 2025, which had discouraged use.
What the FDA is doing
The agency says it is working with six drug-device manufacturers to expand supply — fast-tracking regulatory submissions and urging companies to boost output through additional production shifts, larger batch sizes and specialized equipment. The article didn’t give figures on the shortage’s size or when it’s expected to ease.
Why it matters
Drug shortages force patients and clinicians to scramble for alternatives — different doses, formulations (gels, pills, sprays) or brands — which can disrupt carefully managed treatment. For people relying on estradiol for menopause symptoms or gender-affirming care, consistent access matters. Anyone affected should talk with their prescriber or pharmacist about options rather than stopping therapy on their own. This article is informational and not medical advice.